Profile data is unavailable for this security.
About the company
Oryzon Genomics SA, is a Spain-based clinical phase biopharmaceutical company, which discovers and develops drugs based on epigenetics for the treatment of oncological and neurological diseases. Its compounds in clinical development include iadademstat (ORY-lOOl), an LSD1 inhibitor that is in Phase II trials for the treatment of acute myeloid leukemia and small cell lung cancer; and vafidemstat (ORY-2001), an LSD1 inhibitor optimized for the Central Nervous System (CNS), in multiple Phase II clinical trials for the treatment of CNS and psychiatric illnesses. The Company also has ORY-3001, in preclinical development for the treatment of non-oncological diseases and has additional programs to develop inhibitors against other epigenetic targets.
- Revenue in EUR (TTM)0.00
- Net income in EUR-3.35m
- Incorporated--
- Employees44.00
- LocationOryzon Genomics SASant Ferran 74CORNELLA DE LLOBREGAT 08940SpainESP
- Phone+34 935151313
- Fax+34 933774028
- Websitehttp://www.oryzon.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Eurofins-Cerep SA | 46.17m | 9.21m | 109.96m | 233.00 | 11.94 | 1.83 | 9.82 | 2.38 | 1,826.41 | 1,826.41 | 9,160.00 | 11,939.29 | 0.6814 | 1.66 | 6.04 | 220,892.00 | 13.60 | 15.19 | 16.06 | 18.94 | 85.57 | 67.30 | 19.95 | 19.72 | 5.17 | 112.42 | 0.00005 | 0.00 | 14.45 | 14.30 | 17.09 | 24.52 | -- | -- |
Arcticzymes Technologies ASA | 10.19m | 1.60m | 110.95m | 61.00 | 68.75 | 4.20 | 51.57 | 10.89 | 0.3702 | 0.3702 | 2.35 | 6.07 | 0.3618 | 0.5941 | 2.43 | -- | 5.69 | 15.52 | 6.12 | 17.16 | 95.02 | 96.69 | 15.74 | 33.10 | 12.43 | -- | 0.0392 | -- | -13.16 | 12.24 | -43.02 | -- | 47.93 | -- |
Medica SpA | 63.83m | 3.26m | 112.34m | 706.00 | 34.43 | 2.28 | 11.57 | 1.76 | 0.7727 | 0.7727 | 15.11 | 11.68 | 0.5817 | 1.07 | 5.22 | 90,672.33 | 2.26 | -- | 3.31 | -- | 58.28 | -- | 3.88 | -- | 0.8276 | 4.21 | 0.3487 | -- | 16.13 | -- | -12.52 | -- | -- | -- |
DBV Technologies SA | 4.88m | -94.13m | 116.00m | 88.00 | -- | 0.7576 | -- | 23.78 | -0.999 | -0.999 | 0.0518 | 1.59 | 0.0209 | -- | 0.3738 | 70,687.35 | -40.35 | -64.67 | -46.22 | -80.94 | -- | 91.59 | -1,929.97 | -1,345.10 | -- | -- | 0.0128 | -- | -15.14 | -18.45 | 2.08 | -- | -38.41 | -- |
Turk Ilac Ve Serum Sanayi AS | 55.06m | 3.04m | 116.42m | 439.00 | 38.26 | 3.29 | 29.25 | 2.11 | 0.6534 | 0.6534 | 11.82 | 7.60 | 1.28 | 32.39 | 3.39 | 4,358,227.00 | 7.07 | 3.18 | 11.06 | 5.52 | 22.43 | 23.44 | 5.53 | 2.36 | 1.20 | 1.67 | 0.25 | -- | 16.88 | 81.44 | 229.47 | 49.00 | 37.65 | -- |
Santhera Pharmaceuticals Holding AG | 105.92m | 56.13m | 117.19m | 46.00 | -- | 1.70 | -- | 1.11 | -17.28 | -17.28 | 9.14 | 5.34 | 1.19 | 3.37 | 63.69 | -- | 63.20 | -33.83 | 136.70 | -52.56 | 96.87 | 86.74 | 52.99 | -79.40 | 0.75 | 3.57 | 0.2628 | -- | 1,283.33 | 26.70 | 177.08 | -- | 1.87 | -- |
Adocia SA | 5.73m | -20.55m | 120.52m | 100.00 | -- | -- | -- | 21.05 | -2.36 | -2.36 | 0.6532 | -1.90 | 0.1823 | -- | 16.79 | 55,048.08 | -65.43 | -25.65 | -341.43 | -37.22 | -- | -- | -358.85 | -101.11 | 0.5924 | -2.78 | 2.81 | -- | 692.73 | -10.08 | 69.67 | -- | -40.08 | -- |
Oryzon Genomics SA | 0.00 | -3.35m | 124.05m | 44.00 | -- | 1.47 | -- | -- | -0.0533 | -0.0533 | 0.00 | 1.34 | 0.00 | 143.81 | -- | 0.00 | -3.18 | -4.20 | -3.82 | -4.82 | -- | -- | -- | -- | 0.8694 | -2.93 | 0.1434 | -- | -- | -- | 20.76 | -- | 15.52 | -- |
Molecular Partners AG | 7.21m | -63.51m | 124.83m | 168.00 | -- | 0.6238 | -- | 17.31 | -1.89 | -1.89 | 0.2147 | 5.37 | 0.0306 | -- | 4.74 | 41,892.86 | -26.91 | -11.83 | -28.90 | -14.69 | -- | 99.28 | -880.70 | -45.30 | -- | -70.97 | 0.0203 | -- | -96.29 | -7.43 | -152.59 | -- | -1.40 | -- |
Faron Pharmaceuticals Oy | 0.00 | -30.94m | 125.95m | 34.00 | -- | -- | -- | -- | -0.4067 | -0.4067 | 0.00 | -0.1889 | 0.00 | -- | -- | 0.00 | -287.97 | -213.06 | -- | -963.12 | -- | -- | -- | -- | -- | -12.02 | -- | -- | -- | -- | -7.71 | -- | -16.05 | -- |
Futura Medical PLC | 3.62m | -7.60m | 129.41m | 12.00 | -- | 20.25 | -- | 35.77 | -0.0219 | -0.0219 | 0.0105 | 0.0182 | 0.3391 | -- | 4.73 | -- | -71.22 | -79.25 | -127.75 | -127.22 | 57.22 | -- | -210.03 | -914.37 | 1.47 | -- | -- | -- | -- | -- | -11.40 | -- | 219.68 | -- |
Photocure ASA | 42.91m | 22.88k | 131.32m | 106.00 | 7,869.08 | 3.18 | 54.81 | 3.06 | 0.0072 | 0.0072 | 18.58 | 17.79 | 0.7001 | 0.8203 | 9.37 | -- | 0.0375 | -3.09 | 0.0429 | -3.56 | 94.78 | 93.64 | 0.0535 | -5.19 | 4.32 | -- | 0.00 | -- | 27.35 | 22.50 | 100.37 | -- | 49.83 | -- |
Devyser Diagnostics AB | 14.53m | -4.60m | 131.41m | 118.00 | -- | 3.97 | -- | 9.04 | -3.31 | -3.31 | 10.46 | 23.65 | 0.335 | 1.59 | 5.53 | 1,434,746.00 | -10.65 | -8.97 | -12.00 | -10.15 | 85.53 | 80.14 | -31.78 | -23.91 | 5.11 | -- | 0.1626 | -- | 33.71 | 28.59 | -16.64 | -- | 44.59 | -- |
Transgene SA | 7.63m | -22.33m | 133.73m | 158.00 | -- | 8.54 | -- | 17.52 | -0.2227 | -0.2227 | 0.0759 | 0.1553 | 0.1368 | -- | 4.28 | 48,316.46 | -40.00 | -24.81 | -50.27 | -29.79 | -- | -- | -292.48 | -193.24 | -- | -- | 0.4764 | -- | -23.68 | 1.51 | 31.94 | -- | 14.44 | -- |
Hansa Biopharma AB | 14.24m | -72.53m | 134.66m | 166.00 | -- | -- | -- | 9.46 | -16.07 | -16.07 | 3.15 | -7.10 | 0.1424 | 64.03 | 1.86 | 987,386.90 | -72.51 | -47.96 | -92.27 | -56.12 | 56.80 | 64.18 | -509.33 | -835.04 | 2.55 | -9.65 | 1.65 | -- | -13.22 | 109.06 | -36.09 | -- | -35.24 | -- |
Ose Immunotherapeutics SA | 2.23m | -23.00m | 137.79m | 62.00 | -- | 5.95 | -- | 61.87 | -1.18 | -1.18 | 0.1166 | 1.06 | 0.0256 | -- | 3.22 | -- | -26.46 | -17.17 | -33.15 | -20.55 | -- | -- | -1,032.87 | -94.71 | -- | -97.81 | 0.6659 | -- | -87.83 | -38.07 | -29.52 | -- | -17.11 | -- |
Holder | Shares | % Held |
---|---|---|
SSgA Funds Management, Inc.as of 04 Apr 2024 | 136.22k | 0.22% |
Dimensional Fund Advisors LPas of 04 Apr 2024 | 90.29k | 0.15% |
Santander Private Banking Gestion SA SGIICas of 31 Dec 2023 | 50.00k | 0.08% |
Gescooperativo SA SGIICas of 31 Dec 2023 | 47.91k | 0.08% |
Tressis Gesti�n SGIIC SAas of 31 Dec 2023 | 45.00k | 0.07% |
Solventis SGIIC SAas of 31 Dec 2023 | 20.00k | 0.03% |
Dimensional Fund Advisors Ltd.as of 04 Apr 2024 | 12.54k | 0.02% |
Gesiuris Asset Management SGIIC SAas of 31 Dec 2023 | 8.00k | 0.01% |
Gesti�n de Patrimonios Mobiliarios AV SAas of 31 Mar 2024 | 6.00k | 0.01% |
Andbank Wealth Management SGIIC SAUas of 31 Dec 2023 | 200.00 | 0.00% |